Aerocrine announces prospectus regarding rights issue

Not for publication, release or distribution, directly or indirectly, in or into
the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Japan
or New Zealand.
Press release, 17 April 2012

The prospectus relating to Aerocrine’s rights
issue is now available at www.aerocrine.com and www.remium.com and at
Aerocrine’s offices, Sundbybergsvägen 9, SE-171 73 Solna, Sweden. The prospectus
can also be ordered from Aerocrine by telephone +46 (0)8–629 0780.

 
For
further information, please contact:
Scott Myers, President and CEO of
Aerocrine
Tel: +46-(0)8-629 0780
E-mail: scott.myers@aerocrine.com

Michael
Colérus, CFO
Tel: +46-(0)8-629 0785
E-mail:
michael.colerus@aerocrine.com

 
This press release does not constitute an
offer of any securities of Aerocrine. The rights issue is not directed to
shareholders or other investors domiciled in the United States, Canada,
Australia, Hong Kong, Singapore, South Africa, Japan or New Zealand, or in any
other country where participation in the issue would require additional
prospectuses, registration or other measures other than those pursuant to
Swedish law or would conflict with regulations in such country. No shares,
interim shares, subscription rights or other securities issued by Aerocrine have
been or will be registered in accordance with the United States Securities Act
of 1933, or in accordance with any securities legislation in any state of the
United States or any province in Canada. Accordingly, no new shares, interim
shares, subscription rights or other securities issued by Aerocrine may be
transferred or offered for sale in the United States or Canada, other than in
such exceptional cases that do not require registration. The rights issue is
directed only at (i) persons who are outside the United Kingdom; (ii) investment
professionals falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (as amended); or (iii) persons to whom
it can otherwise lawfully be directed at.

About Aerocrine
AerocrineAB(publ.) is a medical technology company focused on
the improved management and care of patients with inflammatory airway diseases.
As the pioneer and leader in the technology to monitor and manage airway
inflammation, Aerocrine markets NIOX®Flex and NIOX MINO®. Both products enable
fast and reliable management of airway inflammation and may therefore play a
critical role in more effective diagnosis, treatment and follow-up of patients
with inflammatory airway diseases such as asthma. Aerocrine is based
inSwedenwith subsidiaries in theUS,Germanyand theUK. Aerocrine’s shares were
listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the
information provided in this press release pursuant to the Securities Markets
Act. The information was provided for public release on 17 April 2012 at 8:15
PM CET.